Acute Coronary Syndrome Therapy Flashcards
Common causes of ACS (4)
- Atherosclerotic plaque rupture or erosion
- Superimposed platelet aggregation and thrombosis
- Vasospasm and vasoconstriction
- Subtotal or transient total occlusion of vessel
What ACS patient has a high lilelihood of coronary thrombus occluding the infarct artery
STEMI patient
if no PCI has been performed within 2 hours what should be used
Thrombolysis
What type of agents are thrombolytic drugs
Serine proteases
What do thrombolytic agents do
Converts plasminogen to activated state Plasmin
This lyses clots by breaking down fibrin and fibrinogen
What are the 2 types of Thrombolytic agents
Fibrin specific
Non-fibrin specific
Fibrin specific agenst
Alteplase
Reteplase
Tenecteplase
Catalyse conversion of plasminogen to plasmin
Non-fibrin specific agents
Streptokinase
Catalyse systemic fibrinolysis
Contraindication of using thrombolysis (7)
Risk of heavy bleeding:
• Prior intracranial haemorrhage
• Known structural cerebral vascular lesion
• Known malignant intracranial neoplasm
• Ischaemic stroke within 3 months
• Suspected aortic dissection
• Active bleeding or bleeding diathesis (excluding menses)
• Significant closed-head trauma or facial trauma within 3 months
If there is no evidence of STEMI what medication should be used (6)
- Aspirin
- Tigagrelor/Clopidogrel (anti-platelet/blood thinner)
- Fondaparinux/LMW (low molecular weight) heparin (anti-coagulant agents)
- Intravenous nitrate
- Analgesia
- Beta Blockers
What other medications can be used
Prasugrel
Giibiia inhibitors
Statins
Management to reduce risk from NSTEMI
- PCI or CABG
- Aspirin- potent inhibitor of thromboxane A2 production which stimulates aggregation and vasoconstriction
- Clopidogrel, prasugrel, ticagrelor, ticlopidine or cilostazol
- Heparin (LM)
- Fondaparinux
- Giib/iiia receptor blockers
- Statins
- B blockers
What is the mechanism of aspirin
Inhibits the production of thromboxane A2 which stimulates aggregation and vasoconstriction
When can aspirin be used daily (3)
Acute MI
Unstable angina
Secondary prevention
What is the mechanism of clopidogrel
Anti-platelet
Prodrug
Inhibits ADP receptor activated platelet aggregation of platelets and crosslinking of fibrin